Latest news for Syensqo (OTC:SHBBF) Stock

Syensqo is a spinoff of Solvay, a Belgium-based producer of essential and specialty chemicals, founded in 1863. The demerger was undertaken in 2022 and encompasses Solvay's specialty chemicals and materials business units. Syensqo is a leading manufacturer of high-performance materials and specialty surfactants that operates through two main segments. The materials segment (60% of sales) includes specialty polymers and composite materials mainly for applications in autos, aerospace, and electronics. Consumer and resources (40% of sales) include Novecare, technology solutions, aroma performance, and oil and gas, and serves consumer goods end markets. Geographical exposure is well balanced with North America and the Asia-Pacific each contributing around 40% of sales and the rest from Europe.

SPECIALTY HOLDCO BELGIUM by SPECIALTY HOLDCO BELGIUM BV

Syensqo SA

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 edging lower on Friday.
The Dow traded down 0.14% to 43,851.19 while the NASDAQ rose 0.04% to 19,911.75. The S&amp;P 500 also fell, dropping, 0.04% to 6,048.90.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a>
Leading and Lagging Sectors Information technology shares jumped by 0.3% on Friday.
In trading on Friday, materials shares fell by 1.1%.
Top Headline
U.S. import prices increased by 0.1% from the previous month in November. Export prices came in unchanged for November compared to a 1% gain in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) shares shot up 86% to $6.09 following the company's confirmation of its subsidiary WISeSat.Space's satellite launch with SpaceX. The goal of the launch is to deploy post-quantum-ready next-generation WISeSat satellites. This will showcase the combination of WISeKey's Root of Trust and SEALSQ's Post-Quantum Chips, providing security against emerging quantum threats.</li>
<li>Shares of Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) got a boost, surging 22% to $220.24 after the company posted better-than-expected earnings for its fourth quarter.</li>
<li>RH &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares were also up, gaining 13% to $430.78 after the company raised its guidance. Also, Baird maintained a Neutral rating on the stock and raised its price target from $300 to $400.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) shares dropped 57% to $1.6895 after the company reported results of Lunresertib and Camonsertib combination from MYTHIC Phase 1 gynecologic expansion clinical trial.</li>
<li>Shares of 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) were down 35% to $0.0480 after the company announced a 1-for-135 reverse stock split.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) was down, falling 38% to $2.34 after the company announced a public offering of 10 million shares for gross proceeds of $30 million.</li>
</ul>
Commodities In commodity news, oil traded up 1.8% to $71.25 while gold traded down 1.3% at $2,675.00.
Silver traded down 1.8% to $31.050 on Friday, while copper fell 1.1% to $4.1985.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.53%, Germany's DAX fell 0.10% and France's CAC 40 fell 0.15%. Spain's IBEX 35 Index slipped 0.11%, while London's FTSE 100 fell 0.14%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 0.95%, Hong Kong's Hang Seng Index dipping 2.09%, China's Shanghai Composite Index tumbling 2.01% and India's BSE Sensex gaining 1.04%.
Economics
<ul>
<li>U.S. import prices increased by 0.1% from the previous month in November.</li>
<li>U.S. export prices came in unchanged for November compared to a 1% gain in the previous month.</li>
<li>The total number of active U.S. oil rigs came in unchanged at 482 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42483544/how-to-earn-500-a-month-from-meta-stock">How To Earn $500 A Month From Meta Stock</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AVGO

RPTX

WKEY

XXII

Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41384005/amicus-therapeutics-settles-patent-lawsuit-teva-pharmaceuticals-over-generic-version-of-its-rare-" rel="noreferrer noopener">Galafold patent litigation</a> with Teva Pharmaceutical Industries Ltd.
The analyst notes that Amicus is well-positioned, but expectations have increased with the company&#8217;s progress, which are now largely priced into shares.
The analyst downgraded the stock to Equal-weight from Overweight and lowered the price <a target="_blank" href="https://www.benzinga.com/quote/FOLD/analyst-ratings" rel="noreferrer noopener">target from $17 to $12</a>.
Investors have shifted focus to what will provide the company&#8217;s next leg of growth. The analyst would look to see potential updates to the company&#8217;s pipeline in 2025 and beyond, as those programs have the greatest potential to unlock further value for Amicus stock.
Morgan Stanley has also lowered the price target for Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) from $74 to $35 on launch timing and pricing for brenetafusp given disappointing data earlier this year in cutaneous melanoma <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40864698/immunocore-presents-phase-1-data-of-brenetafusp-an-immtac-bispecific-targeting-prame-in-patients-w" rel="noreferrer noopener">and ovarian cancer</a>.
The analyst continues to give full credit for Kimmtrak (tebentafusp), which was approved for unresectable or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42282399/immunocore-announces-reimbursement-agreement-in-england-for-kimmtrak-for-the-treatment-of-hla-a-02" rel="noreferrer noopener">metastatic uveal melanoma</a>.
Morgan Stanley sees limited upside potential from additional brenetafusp updates as the company continues to detect signals in metastatic NSCLC and combination in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41769749/immunocore-reports-third-quarter-financial-results-and-provides-a-business-update" rel="noreferrer noopener">earlier-line NSCLC</a>.
The analyst downgraded the stock <a target="_blank" href="https://www.benzinga.com/quote/IMCR/analyst-ratings" rel="noreferrer noopener">from Overweight to Equal-Weight rating.</a>
Morgan Stanley downgraded Immuneering Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares to Underweight from Equal-weight and set a base case range of $1 to $5 versus its <a target="_blank" href="https://www.benzinga.com/quote/IMRX/analyst-ratings" rel="noreferrer noopener">previous target of $4</a>. While supporting Immuneering&#8217;s strategy of targeting the MAPK pathway with deep cyclic inhibition, the analyst notes other stronger investment opportunities in the coverage on a relative basis.
Early clinical results have been promising, but analysts emphasize the need for more robust data with a larger patient pool to confirm that these outcomes aren&#8217;t coincidental or limited to specific cases. Additionally, the analyst expressed greater caution regarding the potential of IMM-1-104 in indications <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40852429/why-is-nanocap-immuneering-stock-trading-higher-on-friday" rel="noreferrer noopener">outside of pancreatic cancer</a>.
Price Action: IMRX stock is down 18% at $1.615, IMCR stock is down 5.89% at $28.53, and FOLD stock is down 6.70% at $9.47 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468572/netflix-adjusts-parental-leave-policy-amid-cultural-and-financial-shifts" target="_blank" rel="noreferrer noopener">Netflix Adjusts Parental Leave Policy, But There Is A Catch</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Biotech

Downgrades

Health Care

Price Target

Analyst Ratings

Movers

General

FOLD

IMCR

IMRX

TEVA

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Jefferies analyst Julien Dumoulin-Smith maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Buy and raises the price target from $348 to $391.

Jefferies Maintains Buy on GE Vernova, Raises Price Target to $391

U.S. asset manager VanEck has published its predictions for cryptocurrency prices in 2025, anticipating further <a href="https://www.benzinga.com/money/bitcoin-price-prediction">bullish price action next year</a>.
Prediction #1: New Highs For The Crypto Bull Market
VanEck expects the crypto market to reach a medium-term peak in the first quarter of 2025, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) potentially hitting $180,000 and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) exceeding $6,000. 
Altcoins such as Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) and Sui (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SUI</a>) are predicted to experience significant gains as well. 
Following a 30% BTC retracement and deeper altcoin pullbacks (up to 60%) by summer, the market is forecast to rebound, achieving new all-time highs by Q4.
Indicators of a market top include high funding rates, excessive unrealized profits, declining Bitcoin dominance, overvalued MVRV ratios and rising mainstream speculation. &nbsp;
Prediction #2: The U.S. Embraces Bitcoin And Rising Crypto Adoption
The U.S. is positioning itself as a global leader in Bitcoin adoption, thanks to <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42422705/donald-trump-would-welcome-150000-bitcoin-early-in-presidency-its-another-stock-market-for-him">pro-crypto policies</a> and initiatives, such as <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42480856/donald-trump-pledges-to-do-something-great-with-crypto-heres-what-hes-done-so-far">crypto-friendly leadership</a>, <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42487721/bitcoin-much-better-than-gold-as-reserve-asset-says-crypto-hedge-fund-founder">Bitcoin reserves</a>, <a href="https://www.benzinga.com/news/events/24/12/42486099/how-bitcoin-miners-assist-energy-grids-partner-with-renewable-energy-projects">expanding Bitcoin mining</a> and <a href="https://www.benzinga.com/news/events/24/12/42441532/what-does-fair-value-accounting-mean-for-bitcoin-in-corporate-strategy">corporate Bitcoin holdings</a>. 
By 2025, the U.S. is expected to increase its share of global crypto developers from 19% to 25%.
Prediction #3: The Tokenized Securities Market Grows
 VanEck forecasts that <a href="https://www.benzinga.com/topic/tokenization">tokenized securities</a> will exceed $50 billion in value in 2025. 
These securities promise greater efficiency, decentralization and transparency in the financial system. 
Currently, around $12 billion in tokenized securities exist, with $9.5 billion in private credit securities on the Provenance blockchain.
Prediction #4: Stablecoins As The ‘The Trojan Horse' To More Adoption 
<a href="https://www.benzinga.com/news/events/24/12/42348790/stablecoins-a-new-tool-for-us-dollar-dominance-global-financial-access">Stablecoins</a> are expected to play a crucial role in global commerce, with daily settlement volumes reaching $300 billion by the end of 2025. 
This growth is fueled by major player integration and remittance expansion, making stablecoins the &#8220;Trojan Horse&#8221; for blockchain adoption.
Prediction #5: The Rise Of AI Agents
<a href="https://www.benzinga.com/24/12/42446686/google-introduces-ai-agent-prototype-that-can-browse-the-web">AI agents</a> are set to surpass 1 million active on-chain agents by 2025, revolutionizing sectors like DeFi and social media. 
These specialized bots autonomously optimize outcomes, such as yield maximization or engagement boosting, with platforms like Virtuals making agent creation accessible to non-technical users.
Prediction #6: Bitcoin Layer-2 Solutions Transform DeFi 
By 2025, <a href="https://www.benzinga.com/24/08/40528679/layer-2-blockchains-were-all-the-rage-for-crypto-investors-but-layer-1-blockchains-made-them-way-mor">Bitcoin Layer-2 solutions</a> are expected to reach a total value locked (TVL) of 100,000 BTC, addressing Bitcoin's scalability issues while facilitating lower-latency transactions, higher throughput and smart contract functionality in decentralized finance.
Prediction #7: Ethereum&#8217;s Expanding Role
Ethereum&#8217;s Blob Space is forecasted to generate over $1 billion in fees by 2025, solidifying its role as the settlement layer for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38090103/ethereum-layer-2-networks-to-exceed-1-trillion-valuation-by-2030-says-expert">Layer-2 (L2) ecosystems</a>. 
This data layer will process compressed transaction histories, ensuring Ethereum captures value from its Layer-2 network and helping to scale the blockchain.
Additional Predictions for 2025:
<ul>
<li>DeFi Growth: DeFi is expected to reach $4 trillion in DEX volumes and $200 billion in total value locked (TVL).</li>
<li>NFT Market Recovery: The NFT market is projected to recover, with trading volumes reaching $30 billion.</li>
<li>DApp Tokens Outperform L1 Tokens: DApp tokens are expected to narrow the performance gap with Layer-1 tokens.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42446715/bitcoins-next-move-105-000-or-85-000-poll-finds-over-60-say?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=real_estate">Bitcoin&#8217;s Next Move: $105,000 Or $85,000? Poll Finds Over 60% Say&#8230;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

$SUI

Bitcoin To $180,000, Ethereum Over $6,000, Solana To $500: VanEck's 2025 Crypto Predictions

ATIF

ATIF Announces Plan To Change Nasdaq Ticker Symbol To "ZBAI" By End Of Dec.

Deep-pocketed investors have adopted a bullish approach towards Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABNB usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Airbnb. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 66% leaning bullish and 25% bearish. Among these notable options, 4 are puts, totaling $348,588, and 8 are calls, amounting to $427,551.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $130.0 to $145.0 for Airbnb over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Airbnb stands at 2140.78, with a total volume reaching 3,319.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Airbnb, situated within the strike price corridor from $130.0 to $145.0, throughout the last 30 days.
<h3>Airbnb 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734116579_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$135.00</td>
<td>$264.0K</td>
<td>511</td>
<td align="right">388</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$7.25</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$130.00</td>
<td>$141.2K</td>
<td>4.2K</td>
<td align="right">213</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.9</td>
<td>$6.85</td>
<td>$6.9</td>
<td>$130.00</td>
<td>$69.0K</td>
<td>4.2K</td>
<td align="right">213</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.51</td>
<td>$1.5</td>
<td>$1.51</td>
<td>$145.00</td>
<td>$60.4K</td>
<td>5.9K</td>
<td align="right">454</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.82</td>
<td>$2.69</td>
<td>$2.82</td>
<td>$140.00</td>
<td>$42.3K</td>
<td>4.8K</td>
<td align="right">491</td>
</tr>
</tbody>
</table>

<h3>About Airbnb</h3>
Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency, also offering booking services for boutique hotels and experiences. Airbnb's platform offered over 8 million active accommodation listings as of Sept. 30, 2024. Listings from the company's over 5 million hosts are spread over almost every country in the world. In 2023, 50% of revenue was from the North American region. Transaction fees for online bookings account for all its revenue.
Having examined the options trading patterns of Airbnb, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Airbnb Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,537,634, the ABNB's price is down by -4.19%, now at $131.71. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 60 days.</li>
</ul>
<h3>Expert Opinions on Airbnb</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $127.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from DA Davidson continues to hold a Neutral rating for Airbnb, targeting a price of $131. 
&#x2A; An analyst from Truist Securities persists with their Hold rating on Airbnb, maintaining a target price of $123. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Airbnb options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

ABNB

Airbnb Unusual Options Activity For December 13

Whales with a lot of money to spend have taken a noticeably bullish stance on First Solar.
Looking at options history for First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 45% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $303,190 and 5, calls, for a total amount of $192,375.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $175.0 to $230.0 for First Solar over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for First Solar's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of First Solar's whale trades within a strike price range from $175.0 to $230.0 in the last 30 days. 
<h3>First Solar Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734116574_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$33.85</td>
<td>$33.05</td>
<td>$33.85</td>
<td>$175.00</td>
<td>$108.3K</td>
<td>10</td>
<td align="right">32</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$27.45</td>
<td>$26.9</td>
<td>$26.9</td>
<td>$200.00</td>
<td>$53.8K</td>
<td>3.5K</td>
<td align="right">141</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$21.75</td>
<td>$21.6</td>
<td>$21.75</td>
<td>$200.00</td>
<td>$52.2K</td>
<td>330</td>
<td align="right">24</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$27.45</td>
<td>$26.8</td>
<td>$26.8</td>
<td>$200.00</td>
<td>$50.9K</td>
<td>3.5K</td>
<td align="right">102</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$21.5</td>
<td>$21.5</td>
<td>$21.5</td>
<td>$200.00</td>
<td>$43.0K</td>
<td>330</td>
<td align="right">65</td>
</tr>
</tbody>
</table>

<h3>About First Solar</h3>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
Following our analysis of the options activities associated with First Solar, we pivot to a closer look at the company's own performance.
<h3>Current Position of First Solar</h3>
<ul>
<li>With a trading volume of 795,358, the price of FSLR is up by 0.94%, reaching $198.17.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>Expert Opinions on First Solar</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $230.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on First Solar with a target price of $250. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on First Solar, maintaining a target price of $210. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest First Solar options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

FSLR

First Solar's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bearish stance on Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Goldman Sachs Gr.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 40%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $133,660, and 7 are calls, for a total amount of $249,717.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $700.0 for Goldman Sachs Gr over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Goldman Sachs Gr's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Goldman Sachs Gr's substantial trades, within a strike price spectrum from $300.0 to $700.0 over the preceding 30 days.
<h3>Goldman Sachs Gr Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734116569_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$28.25</td>
<td>$27.5</td>
<td>$27.95</td>
<td>$600.00</td>
<td>$50.6K</td>
<td align="right">116</td>
<td align="right">16</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$33.3</td>
<td>$32.65</td>
<td>$32.95</td>
<td>$600.00</td>
<td>$49.4K</td>
<td align="right">504</td>
<td align="right">15</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$58.75</td>
<td>$58.65</td>
<td>$58.75</td>
<td>$620.00</td>
<td>$47.0K</td>
<td align="right">338</td>
<td align="right">8</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$31.15</td>
<td>$30.35</td>
<td>$30.65</td>
<td>$700.00</td>
<td>$45.9K</td>
<td align="right">551</td>
<td align="right">15</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$91.75</td>
<td>$90.0</td>
<td>$90.88</td>
<td>$525.00</td>
<td>$36.3K</td>
<td align="right">0</td>
<td align="right">4</td>
</tr>
</tbody>
</table>

<h3>About Goldman Sachs Gr</h3>
Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa.
In light of the recent options history for Goldman Sachs Gr, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Goldman Sachs Gr</h3>
<ul>
<li>Currently trading with a volume of 527,739, the GS's price is down by -0.78%, now at $586.98. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 33 days.</li>
</ul>
<h3>What The Experts Say On Goldman Sachs Gr</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $621.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from HSBC downgraded its rating to Hold, setting a price target of $608. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Goldman Sachs Gr, maintaining a target price of $585. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Goldman Sachs Gr, targeting a price of $550. 
&#x2A; An analyst from Keefe, Bruyette &amp; Woods has decided to maintain their Outperform rating on Goldman Sachs Gr, which currently sits at a price target of $686. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Goldman Sachs Gr with a target price of $680. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Goldman Sachs Gr options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

A Closer Look at Goldman Sachs Gr's Options Market Dynamics

DA Davidson analyst Tom Forte maintains Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) with a Buy and lowers the price target from $44 to $35.

LOVE

DA Davidson Maintains Buy on Lovesac, Lowers Price Target to $35

BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed.
For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections.
Looking ahead to fiscal year 2025, initial forecasts and management comments suggest a mixed outlook.
The first half of the year is expected to mirror the challenges of late fiscal year 2024, while the second half could see improvement due to easier year-over-year comparisons, potential economic stimulus in China, and a broader market recovery.
After being cautious for most of the past year, the analyst sees some positive signs. The bioprocess market, important for certain Core Tools vendors, has been improving steadily and is expected to stabilize in 2025.
Although China&#8217;s stimulus has taken longer than expected, it is starting to lead to some new orders.
Valuations are still higher than the historical average, but they aren&#8217;t as high as in previous years, creating some good opportunities for stock picking.
BofA upgraded Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) to Buy from Neutral, maintaining the <a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener">price target of $290</a>.
In 2024, Danaher struggled with challenges like reduced bioprocessing inventory, a slowdown in China, and lower spending from biotech and pharma customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41465140/danahers-q3-earnings-boosted-by-bioprocessing-order-growth-analyst-maintain-stock-r" rel="noreferrer noopener">Danaher&#8217;s Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating</a>
Analysts believe that bioprocessing, an important market, is nearly back to normal and should see steady demand in 2025.
Although China is still facing difficulties, BofA expects a strong increase in orders in the fourth quarter due to stimulus efforts, with positive effects likely starting in 2025.
BofA has also upgraded Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) from Neutral to Buy with a <a target="_blank" href="https://www.benzinga.com/quote/RVTY/analyst-ratings" rel="noreferrer noopener">price target of $138</a>.
The company is at a turning point after making significant business changes in recent years. While management did not provide guidance for fiscal year 2025 at the recent Analyst Day, the long-term strategy remains largely the same.
Even though the market is stabilizing in FY25, Revvity&#8217;s growth is expected to be below its 6-8% target range. As short-term industry challenges continue to lessen, BofA expects Revvity to perform well, bolstered by recent acquisitions.
Price Action: At last check Friday, DHR stock was down 0.15% at $234.14, and RVTY stock was down 1.56% at $114.21.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42488323/drug-price-hikes-unsupported-by-evidence-cost-us-815-million-icer-report" target="_blank" rel="noreferrer noopener">Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report</a></li>
</ul>

Large Cap

Upgrades

RVTY

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

DA Davidson analyst Matthew Summerville maintains Nordson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) with a Buy and lowers the price target from $295 to $285.

NDSN

DA Davidson Maintains Buy on Nordson, Lowers Price Target to $285

DA Davidson analyst Michael Shlisky maintains REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) with a Buy and raises the price target from $33 to $39.

REVG

DA Davidson Maintains Buy on REV Group, Raises Price Target to $39

DA Davidson analyst Michael Baker maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Neutral and raises the price target from $880 to $900.

COST

DA Davidson Maintains Neutral on Costco Wholesale, Raises Price Target to $900

Wedbush initiated coverage on Solid Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>), a gene therapy company focused on treating Duchenne muscular dystrophy (DMD).
DMD is a genetic disease that causes progressive muscle weakness and wasting.
SGT-003 is the leading program in Solid Biosciences' pipeline, with plans to advance additional projects toward clinical trials in 2025.
The therapy uses the AAV-SLB101 capsid and a specialized cargo (nNOS binding domain) to potentially boost dystrophin expression compared to earlier-generation treatments.
While first-generation gene therapy for Duchenne muscular dystrophy (DMD) opens new treatment possibilities, there is still room for improvement. The analyst writes that Solid Biosciences' innovative approach and novel capsid technology could enhance microdystrophin delivery.
Although the company's pipeline offers multiple opportunities, current projections focus only on SGT-003 for DMD.
The most significant near-term milestone for Solid Biosciences is the initial Phase 1/2 INSPIRE DUCHENNE trial results, expected in the first quarter of 2025.
Approving Sarepta Therapeutics Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) Elevidys was a key milestone in treating Duchenne muscular dystrophy (DMD), but it's only the beginning. Newer treatments with better and more reliable results are still needed.
Wedbush analyst writes, "We see Solid Biosciences in a "solid" position to deliver a next-gen therapeutic option."
Wedbush writes that Solid Biosciences' stock trade at around $5 each, with about $4 per share in cash providing some downside protection.
Assuming Solid Biosciences' SGT-003 program follows a timeline similar to Sarepta's Elevidys, even a one-year delay would lower the price target to $11 per share (current price target of $16)—still above the current trading price.
With other programs yet to be included in the valuation, the analyst sees strong potential and initiates <a target="_blank" href="https://www.benzinga.com/quote/SLDB/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>.
Solid Biosciences ended the third quarter of 2024 with approximately $171.1 million in cash, cash equivalents, and available-for-sale securities, with an anticipated cash runway into 2026.
Price Action: SLDB stock is up 3.21% at $4.83 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" target="_blank" rel="noreferrer noopener">Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing</a></li>
</ul>

Initiation

SLDB

SRPT

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Barclays analyst Brandt Montour highlights that the re-energized consumer and low tariff exposure will benefit the<a target="_blank" href="https://www.benzinga.com/24/12/42369874/the-stocks-to-buy-to-make-2025-even-more-profitable-than-2024" rel="noreferrer noopener"> travel and experiences sectors in 2025.</a>
The analyst points out that the cruise industry has potential for growth, leading to a reshuffling of ratings for cruise and timeshare companies.
Amid such a scenario, the analyst upgraded Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) to Overweight from Equal-Weight, boosting&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/NCLH/analyst-ratings" rel="noreferrer noopener">the price forecast from&nbsp;$28&nbsp;to&nbsp;$32.</a>
The analyst underscores the upgrade, citing its higher beta in a recovering macro environment, exposure to cross-Atlantic travel, and unique multi-year cost opportunities within the cruise industry.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42488220/broadcom-hits-1-trillion-milestone-the-next-magnificent-tech-giant" rel="noreferrer noopener">Broadcom Hits $1 Trillion Milestone: The Next Magnificent Tech Giant?</a>
In a recovering macro environment with a potentially extended cycle, the company is seeing strong demand in European and Alaska sailings for 2025, according to proprietary pricing data.
The analyst writes that the company&#8217;s multi-year cost savings program could drive earnings growth and balance sheet improvements, while concerns about pricing power in a more balanced cruise market are seen as minimal due to the cruise industry&#8217;s continued value compared to alternatives.
Despite short-term challenges, the analyst sees the company as an attractive entry point with strong long-term potential.
Montour also notes that, based on 2026 estimates, the company is particularly undervalued compared to its peers.
Price Action: NCLH shares are trading lower by 0.62% to $26.65 at last check Friday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/24/12/42487128/apples-2025-chip-transition-targets-new-wireless-edge-broadcom-to-retain-key-role" target="_blank" rel="noreferrer noopener">Apple's 2025 Chip Transition Targets New Wireless Edge, Broadcom To Retain Key Role</a></li>
</ul>
Photo by Erin Cadigan via Shutterstock.

NCLH

Norwegian Cruise Line Benefits From Re-energized Consumer Spending And Cost Savings Program, Analyst Says

Financial giants have made a conspicuous bearish move on Johnson &amp; Johnson. Our analysis of options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) revealed 10 unusual trades.
Delving into the details, we found 20% of traders were bullish, while 80% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $272,347, and 4 were calls, valued at $162,746.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $130.0 to $180.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson &amp; Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson &amp; Johnson's substantial trades, within a strike price spectrum from $130.0 to $180.0 over the preceding 30 days.
<h3>Johnson &amp; Johnson Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734115615_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.8</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$145.00</td>
<td>$55.5K</td>
<td>140</td>
<td align="right">102</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.85</td>
<td>$9.65</td>
<td>$9.85</td>
<td>$155.00</td>
<td>$52.2K</td>
<td>3.4K</td>
<td align="right">105</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.25</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$155.00</td>
<td>$50.0K</td>
<td>3.4K</td>
<td align="right">205</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.9</td>
<td>$9.65</td>
<td>$9.9</td>
<td>$155.00</td>
<td>$49.5K</td>
<td>3.4K</td>
<td align="right">155</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.9</td>
<td>$9.7</td>
<td>$9.9</td>
<td>$155.00</td>
<td>$49.5K</td>
<td>3.4K</td>
<td align="right">52</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 3,379,283, with JNJ's price down by -0.06%, positioned at $146.15.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 40 days.</li>
</ul>
<h3>Professional Analyst Ratings for Johnson &amp; Johnson</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $177.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Johnson &amp; Johnson, targeting a price of $175. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Neutral, setting a price target of $166. 
&#x2A; Reflecting concerns, an analyst from Wolfe Research lowers its rating to Outperform with a new price target of $190.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson &amp; Johnson options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 52% leaning bullish and 35% bearish. Among these notable options, 9 are puts, totaling $352,686, and 8 are calls, amounting to $577,375.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $155.0 for Novo Nordisk during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale activity within a strike price range from $75.0 to $155.0 in the last 30 days. 
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734115610_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.35</td>
<td>$3.15</td>
<td>$3.7</td>
<td>$109.00</td>
<td>$185.0K</td>
<td>1.0K</td>
<td align="right">554</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.0</td>
<td>$4.8</td>
<td>$5.0</td>
<td>$110.00</td>
<td>$96.5K</td>
<td>3.9K</td>
<td align="right">253</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$19.0</td>
<td>$17.9</td>
<td>$18.4</td>
<td>$90.00</td>
<td>$91.9K</td>
<td>834</td>
<td align="right">50</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.2</td>
<td>$103.00</td>
<td>$72.9K</td>
<td>2.1K</td>
<td align="right">778</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/03/25</td>
<td>$3.25</td>
<td>$3.05</td>
<td>$3.24</td>
<td>$100.00</td>
<td>$56.6K</td>
<td>342</td>
<td align="right">211</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>Trading volume stands at 3,835,436, with NVO's price down by -2.67%, positioned at $105.72.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 47 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on NVO Options

Deep-pocketed investors have adopted a bullish approach towards Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RKLB usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Rocket Lab USA. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 6 are puts, totaling $303,382, and 10 are calls, amounting to $1,519,077.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $4.0 to $25.0 for Rocket Lab USA over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Rocket Lab USA's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Rocket Lab USA's whale activity within a strike price range from $4.0 to $25.0 in the last 30 days. 
<h3>Rocket Lab USA 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734115605_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$5.9</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$23.00</td>
<td>$570.0K</td>
<td>4.1K</td>
<td>1.5K</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$5.8</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$23.00</td>
<td>$285.0K</td>
<td>4.1K</td>
<td>1.5K</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$5.8</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$23.00</td>
<td>$280.2K</td>
<td>4.1K</td>
<td>512</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$5.8</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$23.00</td>
<td>$114.0K</td>
<td>4.1K</td>
<td>2.2K</td>
</tr>
<tr>
<td>RKLB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$4.4</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$17.00</td>
<td>$86.5K</td>
<td>71</td>
<td>207</td>
</tr>
</tbody>
</table>

<h3>About Rocket Lab USA</h3>
Rocket Lab USA Inc is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments being Launch Services and Space systems. Geographically it serves Japan, Germany, rest of the world and earns key revenue from the United States.
<h3>Current Position of Rocket Lab USA</h3>
<ul>
<li>With a trading volume of 11,082,397, the price of RKLB is up by 7.66%, reaching $24.31.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Rocket Lab USA</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $22.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Rocket Lab USA with a target price of $24. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Rocket Lab USA, maintaining a target price of $22. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on Rocket Lab USA, maintaining a target price of $12. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Rocket Lab USA, targeting a price of $22. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Rocket Lab USA, which currently sits at a price target of $30. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Rocket Lab USA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

RKLB

What the Options Market Tells Us About Rocket Lab USA

WIIM

ONCO

Onconetix shares are trading lower after the company announced it received a Nasdaq notice for a late quarterly report and subsequent filing.

PRTG

Portage Biotech shares are trading lower after the company announced it received a Nasdaq noncompliance letter.

Palm Harbour Capital - Solvay: The Syensqo Spin-Off

Palm Harbour Capital Q1 2024 Investor Letter

NPTVF

SHBBF

SLVYY

SVYSF

SYNSY

Syensqo

Jefferies initiates coverage on Syensqo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SHBBF#OTC">SHBBF</a>) with a Hold rating.

Comments

Syensqo

News

Latest news for Syensqo (OTC:SHBBF) Stock

Wednesday, March 27, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga